CAMBRIDGE, Mass. – Gen9, Inc., a pioneer in the development of scalable technologies for synthesizing and assembling DNA, today announced the appointment of Jennifer A. Camacho as Chief Legal Officer. In this new role, Ms. Camacho will be responsible for the company’s general legal affairs and intellectual property strategy.

“Jennifer is widely regarded as one of the top IP attorneys in the nation and we are honored to welcome her to the Gen9 team,” said Chief Executive Officer Kevin Munnelly. “This is an exciting time of growth for Gen9, as well as for the synthetic biology industry, and Jennifer’s expertise in intellectual property and complex regulatory requirements will be essential as we expand our operations and grow our base of customers in the agbio, chemical engineering and biomedical R&D industries.”

Ms. Camacho joins Gen9 from the Boston office of Greenberg Traurig, LLP, where she was a partner focused on intellectual property. In this capacity, she represented clients in synthetic biology, industrial biotechnology, pharmaceuticals, regenerative medicine, protein engineering, chemistry, and biofuels, among others. Prior, Ms. Camacho was a partner at the New York-based law firm of Proskauer Rose LLP. Her corporate experience includes vice president of IP and Chief Patent Counsel at Codon Devices. Camacho is routinely recognized for her leadership and work, particularly in the life sciences and emerging technology sectors. She was named an “IP Star” by Managing Intellectual Property magazine and was awarded the Tech Luminary and Innovation All-Star Award by the Boston Business Journal and Mass High Tech. She is a graduate of the University of Illinois at Urbana-Champaign and Boston College Law School.

“The field of synthetic biology represents one of the most exciting areas of technology law and I am looking forward to working with Gen9 and its customers who are using synthetic DNA to drive the innovation in constructive biology,” said Ms. Camacho.

Gen9 also announced today that it has moved into a new state-of-the-art business office and laboratory facility at Riverside Technology Center, located at 840 Memorial Drive in Cambridge, Mass. The facility represents a doubling of space for Gen9, and will allow Gen9 to further increase their state-of-art research, development and manufacturing capabilities.

Gen9 has developed unique, next-generation technologies for synthesizing and assembling DNA constructs for use in numerous synthetic biology applications, including antibody, peptide and enzyme engineering; gene and pathway building; and genome construction. Today, Gen9 is manufacturing and shipping double-stranded GeneBit™ GeneByte™, and GeneByte Plus™ DNA constructs, or gene fragments from 500 to 10,000 base pairs long, and is dedicated to providing solutions to our growing list of customers. The company’s innovative BioFab® platform has the capacity to generate tens of thousands of synthetic gene fragments per year in just a few square feet of laboratory space. Gen9 is the leader in the area of next generation gene synthesis, and continues to focus on innovation, collaboration, dedication and integrity in all aspects of our work.

More information can be found at www.Gen9Bio.com.

About Gen9

Gen9 is the premier next-generation gene synthesis company focused on high-quality, high-throughput, automated production of DNA constructs. The Gen9 technology allows for the lowest-cost and highest-quality DNA constructs commercially available. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels. Gen9 is powering the synthetic biology revolution from our headquarters in Cambridge, Mass., and can be found online at www.gen9bio.com.

Gen9, GeneBit, GeneByte and BioFab are trademarks or registered trademarks of Gen9, Inc. All other brands may be trademarks of their respective holders.

Media Contact

Colin Sanford

203-340-2441

colin@bioscribe.com